Nephroprotection by SGLT2i in CKD Patients: May It Be Modulated by Low-Protein Plant-Based Diets?

Sodium-glucose-transporter 2 inhibitors (SGLT2i) are a new class of anti-diabetic drugs that in large trials such as CREDENCE have shown also a reduction of glomerular hyperfiltration and albuminuria in type 2 diabetic patients. Hence, the interest toward SGLT2i is focused toward this potential neph...

Descripción completa

Detalles Bibliográficos
Autores principales: Cupisti, Adamasco, Giannese, Domenico, Moriconi, Diego, D'Alessandro, Claudia, Torreggiani, Massimo, Piccoli, Giorgina B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793896/
https://www.ncbi.nlm.nih.gov/pubmed/33425967
http://dx.doi.org/10.3389/fmed.2020.622593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793896/
https://www.ncbi.nlm.nih.gov/pubmed/33425967
http://dx.doi.org/10.3389/fmed.2020.622593

Ejemplares similares